Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study

[1]  R. Weichselbaum,et al.  Clinical and molecular markers of long‐term survival after oligometastasis‐directed stereotactic body radiotherapy (SBRT) , 2016, Cancer.

[2]  J. Y. Lee,et al.  A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  P. Iyengar,et al.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Gomez,et al.  Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. , 2014, International journal of radiation oncology, biology, physics.

[5]  David A. Palma,et al.  The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.

[6]  M De Ridder,et al.  Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Niibe,et al.  A Call for the Aggressive Treatment of Oligometastatic and Oligo-Recurrent Non-Small Cell Lung Cancer , 2012, Pulmonary medicine.

[9]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  D. Gomez,et al.  Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. , 2012, International journal of radiation oncology, biology, physics.

[11]  R. Weichselbaum,et al.  MicroRNA Expression Characterizes Oligometastasis(es) , 2011, PloS one.

[12]  C. Gridelli,et al.  PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Cleeland,et al.  Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. , 2011, The oncologist.

[14]  H. Dienemann,et al.  Surgical treatment of oligometastatic non-small cell lung cancer. , 2010, Lung cancer.

[15]  R. Onimaru,et al.  Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. , 2010, Japanese journal of clinical oncology.

[16]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[17]  B. Milleron,et al.  Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. , 2010 .

[18]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[19]  A. Rademaker,et al.  Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Kavanagh,et al.  Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis , 2009, Acta oncologica.

[21]  R. Weichselbaum,et al.  An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease , 2008, Clinical Cancer Research.

[22]  R. Abrams,et al.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  S. Hassenbusch,et al.  Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis , 2006, Cancer.

[24]  A. Iwasaki,et al.  Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  M. Kris,et al.  A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. , 2002, Lung cancer.

[26]  Daniel Zelterman,et al.  Modeling Survival Data: Extending the Cox Model , 2002, Technometrics.

[27]  D. Miller,et al.  Surgical treatment of primary lung cancer with synchronous brain metastases. , 2001, The Journal of thoracic and cardiovascular surgery.

[28]  M. Riquet,et al.  Surgical management of non-small cell lung cancer with synchronous brain metastases. , 2001, Chest.

[29]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[30]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  E. Glatstein.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC) , 2008 .